Jazz Pharmaceuticals (JAZZ)
(Delayed Data from NSDQ)
$105.09 USD
-1.38 (-1.30%)
Updated Jul 2, 2024 04:00 PM ET
After-Market: $105.05 -0.04 (-0.04%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
JAZZ 105.09 -1.38(-1.30%)
Will JAZZ be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for JAZZ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for JAZZ
Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates
JAZZ Falls as Suvecaltamide Tremor Study Fails to Meet Goals
JAZZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Jazz (JAZZ) Down 3.5% Since Last Earnings Report?
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates
Other News for JAZZ
7 Biotech Stocks to Boost Your Portfolio to Peak Health
3 Cannabis Stocks That Could Make Your Grandchildren Rich
Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues
Maintaining a Buy Rating: Jazz Pharmaceuticals’ Solid Prospects Despite Clinical Trial Setbacks
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), Jazz Pharmaceuticals (JAZZ) and Legend Biotech (LEGN)